Roivant reports first LISRAYA sales of $31.0 million and misses on Immunovant trial
Roivant reported $31.0 million in LISRAYA net product revenue in its first five weeks of launch, and a $0.27 per share net loss for the quarter ended September 30, 2026.
Key takeaways
- Roivant (ROIV) reported $31.0 million in LISRAYA net product revenue in its first five weeks of launch after U.S. approval in August 2026. The company reported a net loss of $191.6 million, or $0.27 per share, for the quarter ended September 30, 2026. Cash and marketable securities totaled $4.2 billion.
Roivant (ROIV) reported $31.0 million in net product revenue from LISRAYA, its brepocitinib drug, in the first five weeks after its August 2026 U.S. launch.
The net loss attributable to Roivant Sciences Ltd. was $191.6 million, or $0.27 per share, for the quarter ended September 30, 2026, versus $113.5 million, or $0.17 per share, a year earlier.
Shares rose 2.9% premarket at 8:18 a.m. ET, from a $38.88 close.
Trial and pipeline updates
IMVT-1402 at 600 mg met the primary ACR20 endpoint at Week 28 in Period 2 of the potentially registrational trial in difficult-to-treat rheumatoid arthritis, with 92.5% responding against 75.6% on placebo (p-value 0.0139). It is unlikely to advance IMVT-1402 further in Sjögren's disease beyond the ongoing, fully enrolled Phase 2 trial.
Brepocitinib met the primary and all key secondary endpoints in the Phase 3 CLARITY-1 and CLARITY-2 trials in non-infectious uveitis. Priovant intends to file a supplemental New Drug Application in the first half of calendar 2027.
Mosliciguat showed a placebo-adjusted reduction in pulmonary vascular resistance of -56.3% at Week 16 in the Phase 2 PHocus study in pulmonary hypertension associated with interstitial lung disease. The Phase 3 PHrontier study has started enrollment.
Costs and cash
Research and development expenses fell to $145.7 million from $164.6 million a year earlier. Selling, general and administrative expenses rose to $154.1 million from $143.1 million, driven by the LISRAYA launch.
Consolidated cash, cash equivalents and marketable securities were $4.2 billion as of September 30, 2026, including the Moderna payment received in July.
Litigation and upcoming events
In July, Genevant and Arbutus received $950 million from Moderna, the initial payment under a $2.25 billion patent infringement settlement. An additional $1.3 billion payment is contingent on a favorable resolution of Moderna's Section 1498 appeal.
Roivant will hold an Investor Day in New York City and virtually on December 9, 2026.